1LIAO JK, LAUFS U. Pleiotropic effects of statins[J]. Annu Rev Pharmacol Toxicol, 2005, 45 : 89-118.
2RAMASUBBU K, ESTEP J, WHITE DL, et al. Experimental and clinical basis for the use of statins in patients with isehemic and nonischemic cardiomyopathy[J]. Am J Coll Cardiol, 2008, 51(4): 415-426.
3TOUSOULIS D, ANTONIADES C, VASSILIADOU C, et al. Effects of combined administration of low dose atorvastatin and vitamin E on inflammatory markers and endothelial function in patients with heart failure[J]. Eur J Heart Fail, 2005, 7 (7): 1126-1132.
4SOLA S, MIR MQ, LERAKIS S, et al. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure[J]. J Am Coll Cardiol, 2006. 47(2) : 332-337.
5MOZAFFARIAN D, MINAMI E, LETTERER RA, et al. The effects of atorvastatin (10 mg) on systemic inflammation in heart failure[J]. Am J Cardiol, 2005, 96(12): 1699-1704.
6BROWN JH, del RE DP, SUSSMAN MA. The Rac and Rho hall of fame : a decade of hypertrophic signaling hits[J]. Circ Res, 2006, 98(6): 730-742.
7MELLIN V, ISABELLE M, OUDOT A, et al. Transient reduction in myocardial free oxygen radical levels is involved in the improved cardiac function and structure after long-term allopurinol treatment initiated in established chronic heart failure [J]. Eur Heart J, 2005, 26( 15 ) : 1544-1550.
8HABIBI J, WHALEY-CONNELL A, QAZI MA, et al. Rosuvastatin, a 3-hydroxy-3-methylglutaryl eoenzyme A reduetase inhibitor, decreases cardiac oxidative stress and remodeling in Ren2 transgenic rats[J]. Endocrinology, 2007, 148 (5): 2181-2188.
9SUN W, LEE TS, ZHU M, et al. Statins activate AMP-activated protein kinase in vitro and in vitro[J]. Circulation, 2006, 114 (24) : 2655-2662.
10STREY CH, YOUNG JM, MOLYNEUX SL, et al. Endothelium-ameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure[J]. Atherosclerosis, 2005, 179(1) : 201-206.
